Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. | The Lancet | 1666 | 1458 | |
2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. | Gastric Cancer | 50 | 43 | |
2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. | Gastric Cancer | 138 | 130 | |
2009 | Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: A case control study | Hu H.-M.; Kuo C.-H.; Lee C.-H.; Wu I.-C.; Lee K.-W.; JANG-MING LEE ; Goan Y.-G.; Chou S.-H.; Kao E.-L.; Wu M.-T.; Wu D.-C. | BMC Gastroenterology | 21 | 18 | |
2018 | Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials | Yen C.-J.; Muro K.; Kim T.-W.; Kudo M.; JIN-YUAN SHIH ; Lee K.-W.; Chao Y.; Kim S.-W.; Yamazaki K.; Sohn J.; Cheng R.; Zhang Y.; Binder P.; Mi G.; Orlando M.; Chung H.C. | Journal of Global Oncology | 9 | 0 | |
2009 | Skin Dose Impact from Vacuum Immobilization Device and Carbon Fiber Couch in Intensity Modulated Radiation Therapy for Prostate Cancer | Lee K.-W.; Wu J.-K.; Jeng S.-C.; Hsueh Liu Y.-W.; CHIA-HSIEN CHENG | Medical Dosimetry | 19 | 17 | |
2013 | Taiwan aneurysm registry: Multivariate analysis of two-month, one-year, and two-year outcomes after endovascular and microsurgical treatment of ruptured aneurysms | HON-MAN LIU ; Wong H.-F.; Lee K.-W.; YONG-KWANG TU ; Yeh Y.-S.; Chou C.-W.; Wang Y.-H.; Chen Y.-L.; Lo Y.-L.; Hsieh T.-C.; Wang Y.-C.; Lin T.-K.; DAR-MING LAI ; Chen W.-L.; Tseng H.-M.; Li C.-W. | Interventional Neuroradiology | 4 | 3 |